AbbVie Reports Will Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hep C Patients
November 11, 2014 at 08:08 AM EST
AbbVie (NYSE: ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of ...